Clorox offers an attractive 6% dividend yield with a record date of Oct. 28 for its $1.25 quarterly payout. Investors would need 1,000 shares (approximately $83,440) to generate $5,000 in annual dividends. While the company has raised dividends for 49 consecutive years and is approaching Dividend King status, concerns exist regarding its unsustainable payout ratio exceeding 103% and weak stock performance over the past five years.

In a comparison of two major consumer staples companies, Colgate-Palmolive emerges as the stronger investment choice due to its global diversification, consistent growth profile, and strong emerging-market performance. While Clorox offers a cheaper valuation and transformation potential through its GOJO acquisition and ERP improvements, it faces headwinds from elevated inflation, muted demand, and the need to rebuild organic sales momentum.

The article recommends three consumer staples stocks as long-term holdings: PepsiCo, which is pivoting toward healthier products with improving financials and a low P/E ratio; J.M. Smucker, benefiting from strong coffee brands and rising profitability; and Clorox, a distressed company offering an attractive 6.1% dividend yield despite current challenges. All three stocks feature strong brand portfolios and consistent dividend growth histories.

Clorox has faced significant difficulties since the economic reopening following the pandemic boom. The company, which experienced strong business during COVID-19, has struggled with multiple challenges in recent years as consumer behavior and market conditions have normalized.

The Clorox Company is executing a strategic transformation focused on rebuilding market share and enhancing growth through the GOJO Industries acquisition, which significantly expands its health and hygiene portfolio to over half of net sales. The company has completed its five-year digital transformation program and expects productivity benefits from fiscal 2027 onwards. Clorox is increasing innovation spending in health, wellness, and pet care categories while improving brand relevance through targeted promotions and packaging improvements.

The Clorox Company (CLX) is experiencing elevated implied volatility in its October 2026 put options, signaling market expectations for significant price movement. However, the fundamental outlook remains weak, with Clorox holding a Zacks Rank #3 (Hold) rating and six analysts downgrading estimates over the past 60 days, reducing consensus earnings estimates from $1.26 to $0.99 per share.

Colgate-Palmolive is strengthening its market position through innovation, premiumization of oral-care products, and expansion in emerging markets. The company is introducing differentiated products targeting whitening, sensitivity, and gum health, while leveraging its strong global brands. However, sustaining momentum depends on balancing pricing with volume, successful product launches, and cost management. Colgate trades at a premium valuation (21.5X forward P/E vs. industry 18.4X) with modest EPS growth projected at 4.9% for 2026 and 5.2% for 2027.

Procter & Gamble faces a $1.4 billion after-tax earnings headwind in fiscal 2027 as it attempts to balance pricing strategies with volume growth in a challenging consumer environment. While pricing contributed to 1% organic sales growth in fiscal 2026, volume remained flat in Q4. PG plans to shift toward more balanced growth through innovation, promotions, and disciplined pricing rather than relying solely on price increases, which risk consumer trade-downs and reduced purchase frequency.

A comparison of two consumer staples stocks reveals that Ahold NV (ADRNY) presents a better value opportunity than Clorox (CLX). ADRNY has a superior Zacks Rank of #2 (Buy) versus CLX's #3 (Hold), along with more attractive valuation metrics including a lower forward P/E ratio (11.70 vs 14.87) and significantly lower P/B ratio (1.93 vs 40.72). ADRNY earned a Value grade of A compared to CLX's C grade.

Newsweek announced its fourth annual World's Most Trustworthy Companies ranking, recognizing 1,000 companies across 20 countries based on customer, employee, and investor trust. Wyndham Hotels & Resorts, Campbell's, Nintendo, Samsung SDS, Linde, Clorox, and Tesco ranked No. 1 in their respective industries. The ranking evaluated over 65,000 survey participants and 200,000 company evaluations across three trust dimensions.

Clorox reported Q4 fiscal 2026 earnings and sales that beat consensus estimates, but the company faced significant challenges including a 42% year-over-year decline in adjusted EPS, a 520 basis point gross margin contraction due to higher commodity and manufacturing costs, and organic sales decline of 13%. The stock has declined 9.3% since earnings, and analysts have downwardly revised estimates by 21.06%, resulting in a Zacks Rank #4 (Sell) rating with expectations for below-average returns.

A comparison of two consumer staples stocks reveals that Ahold NV (ADRNY) presents a better value opportunity than Clorox (CLX) for value investors. ADRNY has a stronger Zacks Rank of #2 (Buy) versus CLX's #4 (Sell), along with more attractive valuation metrics including a lower forward P/E ratio (11.26 vs 16.67) and significantly lower P/B ratio (1.8 vs 46.88).